NCT06314672 Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial
| NCT ID | NCT06314672 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Hematopoietic and Lymphoid System Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 208 participants |
| Start Date | 2023-08-22 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 208 participants in total. It began in 2023-08-22 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial tests the impact of the The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) project on clinical trial referrals and enrollment in racial/ethnic minorities. Progress in cancer prevention, detection and treatment can only be made by identifying and validating new and improved methods, compounds and modalities in clinical trials. Unfortunately, participation in clinical trials is not equal across all racial and ethnic groups, limiting progress against cancer in all population groups and further widening the disparity gap. To change this picture, concerted effort needs to be directed both at the communities at risk for being left out of trials and the systems that cause the disparities at all levels involved in accrual to clinical trials. The CUSP2CT project may have the potential to increase referral and accrual of racial/ethnic minorities to prevention/control and treatment trials.
Eligibility Criteria
Inclusion Criteria: * Phase I: 9 counties in the OSUCCC catchment area * Phase II: Patients, providers, and hospital systems/referral centers that directly addresses challenges identified in Phase I * Phase II: The project will involve the OSUCCC, the OSU James Cancer Network sites and the Columbus and Dayton NCORP sites
Contact & Investigator
Electra D Paskett, PhD
PRINCIPAL INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06314672 clinical trial?
This trial is open to participants of all sexes, studying Hematopoietic and Lymphoid System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06314672 currently recruiting?
Yes, NCT06314672 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.
Where is the NCT06314672 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT06314672 clinical trial?
NCT06314672 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Electra D Paskett, PhD at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 208 participants.